Sugi Predict

Sugi Predict / Compounds / SCHEMBL493879

SCHEMBL493879

SCHEMBL493879

NC(=O)CCCN1CCCCC1

nearest known ligand 0.79

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.79
▸ CYP1A2 P05177 1/20 0.69
▸ MAPK1 P28482 1/20 0.69
▸ SMN1; SMN2 Q16637 1/20 0.69
▸ ALDH1A1 P00352 5/20 0.56
▸ MAPT P10636 3/20 0.56
▸ POLB P06746 1/20 0.56
▸ HRH3 Q9Y5N1 2/20 0.54
▸ ALOX15 P16050 1/20 0.49
▸ TSHR P16473 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ KMT2A Q03164 1/20 0.43
▸ HTR7 P34969 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2710255 0.98 L3MBTL1 (0.76) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1
SCHEMBL3926676 0.98 L3MBTL1 (0.75) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL4710262 0.95 L3MBTL1 (0.72) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1
SCHEMBL3904815 0.93 L3MBTL1 (0.76) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1
SCHEMBL3321939 0.93 L3MBTL1 (0.68) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1
SCHEMBL16395702 0.91 L3MBTL1 (0.73) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1
SCHEMBL5500773 0.91 L3MBTL1 (0.73) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1
SCHEMBL30701390 0.91 L3MBTL1 (0.73) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1
SCHEMBL5506643 0.91 L3MBTL1 (0.73) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1
SCHEMBL10627594 0.91 L3MBTL1 (0.73) L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368650-A1 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS CHIESI FARMACEUTICI S.P.A. (IT) 2025-12-04 — — US claimed
CN-109554004-A Pigment dispersing agent and application thereof 江苏丽王科技股份有限公司 2019-04-02 — — CN claimed
CN-104666299-A 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof GALDERMA RES & DEV 2015-06-03 — — CN claimed
CN-102575137-B adhesive resin composition for silicon wafer ADEKA CORP 2014-11-26 — — CN claimed
US-20080187572-A1 Matrix Metalloproteinase Inhibitors of Tgfb-Induced Subcapsular Cataract Formation MCMASTER UNIVERSITY (CA) 2008-08-07 — — US claimed
EP-1917015-A1 NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-07 — — EP claimed
EP-1877051-A1 MATRIX METALLOPROTEINASE INHIBITORS OF TGFß -INDUCED SUBCAPSULAR CATARACT FORMATION McMaster University (CA) 2008-01-16 — — EP claimed
WO-2007019884-A1 NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 — — WO claimed
WO-2006113993-A1 MATRIX METALLOPROTEINASE INHIBITORS OF TGFß -INDUCED SUBCAPSULAR CATARACT FORMATION MCMASTER UNIVERSITY (CA) 2006-11-02 — — WO claimed
WO-2006089874-A1 BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONES GPC BIOTECH AG (DE) 2006-08-31 — — WO claimed
US-20050256154-A1 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides LUK KIN-CHUN 2005-11-17 — — US claimed
EP-1575947-A1 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES Amgen Inc. (US) 2005-09-21 — — EP claimed
JP-3553083-B2 — — 2004-08-11 — — JP claimed
WO-2004060890-A1 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES AMGEN INC. (US) 2004-07-22 — — WO claimed
EP-0852494-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-15 — — EP claimed
WO-1998025885-A1 ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1998-06-18 — — WO claimed
WO-1997009973-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-03-20 — — WO claimed
US-20250368650-A1 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS CHIESI FARMACEUTICI S.P.A. (IT) 2025-12-04 — — US disclosed
EP-0619816-A1 A PROCESS FOR THE RESOLUTION OF (+-)-ALPHA-[2-[ACETYL(1-METHYLETHYL)AMINO]ETHYL]-ALPHA-(2-CHLOROPHENYL)-1-PIPERIDINEBUTANAMIDE G.D. SEARLE & CO. (US) 1994-10-19 — — EP disclosed
WO-1993013087-A1 A PROCESS FOR THE RESOLUTION OF (+-)-α-[2-[ACETYL(1-METHYLETHYL)AMINO]ETHYL]-α-(2-CHLOROPHENYL)-1-PIPERIDINEBUTANAMIDE G.D. SEARLE & CO. (US) 1993-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256154-A1 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides FGFR3, FGFR4, FGFR1 L3MBTL1 3096/4885CYP1A2 1410/4885MAPK1 1115/4885
US-20250368650-A1 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS ALK, TGFBR2, TGFBR1 L3MBTL1 4590/4885CYP1A2 1599/4885MAPK1 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.